<DOC>
	<DOC>NCT01323634</DOC>
	<brief_summary>The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with COPD.</brief_summary>
	<brief_title>Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This is a randomized, double-blind, double-dummy, multi-centre parallel group study. Subjects who meet the eligibility criteria at Screening and meet the randomization criteria at the end of a 2-week Run-In period will enter a 12-week treatment period. There will be a 7-day Follow-up period after the treatment period.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Signed and dated written informed consent Male or females ≥ 40 years of age Established clinical history of COPD by ATS/ERS definition Females are eligible to enter and participate if of nonchildbearing potential, or if of child bearing potential, has a negative serum pregnancy test at screening, and agrees to one of the acceptable contraceptive methods listed in protocol, used consistently and correctly Former or current smoker &gt; 10 pack years Postalbuterol spirometry criteria: FEV1/FVC ratio ≤ 0.70 and FEV1 ≤ 70% of predicted normal (NHANES III) Current diagnosis of asthma Subjects with other respiratory disorders including active tuberculosis, α1antitrypsin deficiency, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases Lung volume reduction surgery within previous 12 months Clinically significant abnormalities not due to COPD by chest xray Hospitalized for poorly controlled COPD within 12 weeks of Screening Poorly controlled COPD 6 weeks prior to Screening, defined as acute worsening of COPD that is managed by the subject with corticosteroids or antibiotics or that requires treatment prescribed by a physician Lower respiratory infection requiring antibiotics 6 weeks prior to Screening Uncontrolled or clinically significant (in opinion of PI) cardiovascular, hypertension, neurological, psychiatric, renal, hepatic, immunological, endocrine, peptic ulcer disease, or hematological abnormalities Carcinoma not in complete remission for at least 5 years Subjects with history of hypersensitivity to study medications (e.g., betaagonists, corticosteroid) or components of inhalation powder (e.g., lactose, magnesium stearate) Subjects with history of severe milk protein allergy that, in opinion of study physician, contraindicates subject's participation Known/suspected history of alcohol or drug abuse in the last 2 years Women who are pregnant or lactating or plan to become pregnant Subjects medically unable to withhold albuterol and/or ipratropium 4 hours prior to spirometry testing at each study visit Use of certain medications such as bronchodilators and corticosteroids for the protocolspecific times prior to Visit 1 (the Investigator will discuss the specific medications) Long Term Oxygen Therapy (LTOT) or nocturnal oxygen therapy &gt;12 hours a day Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening or during the study Noncompliance or inability to comply with study procedures or scheduled visits Affiliation with investigator site</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>